<DOC>
	<DOCNO>NCT00049699</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness VNP40101M treat patient advanced metastatic cancer .</brief_summary>
	<brief_title>VNP40101M Treating Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect VNP40101M patient advance metastatic solid tumor lymphoma . - Determine maximum tolerate dose drug patient . - Determine pharmacokinetics drug patient . - Determine antitumor effect drug patient . OUTLINE : This dose-escalation study . Patients receive VNP40101M IV 15 minute day 1 , 8 , 15 . Treatment repeat every 28 day . Cohorts 3-6 patient receive escalate dos VNP40101M maximum tolerate dose determine . PROJECTED ACCRUAL : Approximately 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic solid tumor lymphoma curative standard effective therapy exist Measurable evaluable disease Primary brain tumor brain metastasis allow provide neurologic deficit stable preclude study compliance PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy At least 3 month Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hematocrit least 30 % ( transfusion allow ) No bleed diathesis Hepatic PT PTT great 1.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN ALT AST great 1.5 time ULN ( 3 time ULN liver metastasis present ) Albumin least 2.5 gm/dL Renal Creatinine great 2.0 mg/dL Cardiovascular At least 3 month since prior myocardial infarction No symptomatic coronary artery disease No arrhythmia require medication No uncontrolled congestive heart failure Pulmonary No dyspnea minimal moderate exertion DLCO FEV1 least 60 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled active bleeding ( e.g. , active peptic ulcer disease ) No active infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Recovered acute toxicity prior biologic therapy ( persist , chronic toxicity allow stable great grade 1 ) Chemotherapy More 6 month since prior highdose chemotherapy stem cell support More 3 week since prior cytotoxic chemotherapy ( 6 week mitomycin nitrosoureas ) Recovered acute toxicity prior chemotherapy ( persist , chronic toxicity allow stable great grade 1 ) Endocrine therapy At least 2 week since prior hormonal therapy Radiotherapy Recovered acute toxicity prior radiotherapy ( persist , chronic toxicity allow stable great grade 1 ) Surgery At least 2 week since prior surgery Other No concurrent standard investigational treatment cancer No concurrent disulfiram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>